Semaglutide

Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) used to treat type 2 diabetes by enhancing insulin secretion, reducing appetite, and promoting weight loss. It is administered as a subcutaneous injection once weekly and has shown significant efficacy in improving glycemic control and reducing body weight.

Semaglutide and Type 2 Diabetes: Efficacy, Safety, and Outcomes

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar through glucagon suppression.

What's Next for Semaglutide? Beyond Diabetes and Weight Loss

Understanding the impact of weight loss medications on female reproductive health

In recent months, the efficacy of contraception for people taking weight loss medications has been questioned, as several women claim to have gotten pregnant despite using oral contraceptives.

21 Feb 2025

Regulatory crackdown on online prescriptions of weight-loss drugs

Online pharmacies must now conduct in-person consultations before dispensing weight-loss medications, ensuring safe and appropriate use of high-risk drugs.

19 Feb 2025

Medicare Part D beneficiaries face rising out-of-pocket costs for brand name drugs The Expe...

Expected out of-pocket costs for commonly prescribed brand name medications have grown substantially for Medicare Part D beneficiaries as drug plans increasingly tie patient costs to list prices, according to new research from the USC Schaeffer Center for Health Policy & Economics published in JAMA.

19 Feb 2025

New gene switch may lead to precise treatments for metabolic diseases

ETH researchers have developed a new gene switch that can be activated using a commercially available nitroglycerine patch applied to the skin.

17 Feb 2025

Diabetes drugs may boost brain health but experts warn of risks

Researchers reviewed 374 studies to explore how GLP-1RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

16 Feb 2025

Low-dose semaglutide reduces alcohol consumption and cravings in early trial

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

13 Feb 2025

Blockbuster drug for diabetes and obesity could also help reduce alcohol intake

The blockbuster drug semaglutide, better known as Ozempic for diabetes and Wegovy for obesity, could also help people cut down on their alcohol intake, according to new USC research.

12 Feb 2025

Vision loss risks in patients using popular GLP-1 medications raise concerns

A small percentage of patients taking the extraordinarily popular GLP-1 medications have experienced vision problems, but a direct causal link with the drugs has not been established. That is the conclusion of a retrospective study published online on Jan. 30 in JAMA Ophthalmology.

7 Feb 2025

Communication between body muscle and pituitary gland may play unexpected role in female fertility

A newly discovered line of communication between body muscle and the pituitary gland may play an unexpected role in female fertility, according to a new study.

6 Feb 2025

GLP-1 drug exenatide shows no benefit for Parkinson's in new study

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's, finds a new study led by UCL researchers.

4 Feb 2025

High discontinuation rates of GLP-1 agonists found among patients with obesity

Discontinuation of GLP-1 receptor agonists in obesity is common, driven by weight regain and socioeconomic factors, impacting treatment effectiveness.

4 Feb 2025

Prescription trends for obesity medications surge, tied to growing interest in GLP-1 drugs

Obesity medication prescriptions reached 1.5 million, driven by GLP-1 agents semaglutide and tirzepatide, as public interest influences prescription trends.

3 Feb 2025

Gut-derived sugars: A potential game-changer for weight management and diabetes

Gut bacteria-produced exopolysaccharides (EPS) help regulate metabolism by modulating gut microbiota, promoting SCFA production, and improving glucose homeostasis. S. salivarius, a key EPS producer, shows potential for obesity and diabetes intervention.

30 Jan 2025

Revolutionizing diabetes care with innovative targets and therapeutic options

A thorough examination of modern drugs that target particular receptors and metabolic pathways for glucose and fat metabolism is presented. Recent research has revealed innovative targets and therapeutic options.

30 Jan 2025

Weekly diabetes injection could replace daily shots for lipodystrophy patients

Rutgers Health researchers have found that a weekly injection of diabetes medication could replace painful daily hormone shots for people with a rare genetic form of lipodystrophy that leaves patients with almost zero fat tissue, according to a study in The New England Journal of Medicine.

29 Jan 2025